Abbreviations
- AAS:
-
Androgenic/anabolic steroids
- OTC:
-
Over the counter
References
Parkinson AB, Evans NA. Anabolic androgenic steroids: a survey of 500 users. Med Sci Sports Exerc. 2006;38:644–651. doi:10.1249/01.mss.0000210194.56834.5d.
Handelsman DJ, Gupta L. Prevalence and risk factors for anabolic-androgenic steroid abuse in Australian high school students. Int J Androl. 1997;20:159–164. doi:10.1046/j.1365-2605.1997.d01-285.x.
Stimac D, Milic S, Dintinjana RD, Kovac D, Ristic S. Androgenic/anabolic steroid-induced toxic hepatitis. J Clin Gastroenterol. 2002;35:350–352. doi:10.1097/00004836-200210000-00013.
Hartgens F, Kuipers H. Effects of androgenic-anabolic steroids in athletes. Sports Med. 2004;34:513–554. doi:10.2165/00007256-200434080-00003.
Jasiurkowski B, Raj J, Wisinger D, Carlson R, Zou L, Nadir A. Cholestatic jaundice and IgA nephropathy induced by OTC muscle building agent superdrol. Am J Gastroenterol. 2006;101:2659–2662.
Maravelias C, Dona A, Stefanidou M, et al. Adverse effects of anabolic steroids in athletes. A constant threat. Toxicol Lett. 2005;158:167–175. doi:10.1016/j.toxlet.2005.06.005.
Sanchez-Osorio M, Duarte-Rojo A, Martinez-Benitez B, Torre A, Uribe M. Anabolic-androgenic steroids and liver injury. Liver Int. 2007; Epub ahead of print.
Orr R, Fiatorone Singh M. The anabolic androgenic steroid oxandrolone in the treatment of wasting and catabolic disorders: review of efficacy and safety. Drugs. 2004;64:725–750. doi:10.2165/00003495-200464070-00004.
Murphy KD, Thomas S, Mlcak RP, Chinkes DL, Klein GL, Herndon DN. Effects of long-term oxandrolone administration in severely burned children. Surgery. 2004;136:219–224. doi:10.1016/j.surg.2004.04.022.
Hall RC, Hall RC. Abuse of supraphysiologic doses of anabolic steroids. South Med J. 2005;98:550–555. doi:10.1097/01.SMJ.0000157531.04472.B2.
Bagheri SA, Boyer JL. Peliosis hepatis associated with androgenic-anabolic steroid therapy. A severe form of hepatic injury. Ann Intern Med. 1974;81:610–618.
Socas L, Zumbado M, Pérez-Luzardo O, Ramos A, Pérez C, Hernández JR. Hepatocellular adenomas associated with anabolic androgenic steroid abuse in bodybuilders: a report of two cases and a review of the literature. Br J Sports Med. 2005;39:e27. doi:10.1136/bjsm.2004.013599.
Carrasco D, Prieto M, Pallardó L, et al. Multiple hepatic adenomas after long-term therapy with testosterone enanthate. Review of the literature. J Hepatol. 1985;1:573–578. doi:10.1016/S0168-8278(85)80001-5.
Gurakar A, Caraceni P, Fagiuoli S, Van Thiel DH. Androgenic/anabolic steroid-induced cholestasis: a review with four additional case reports. J Okla State Med Assoc. 1994;87:399–404.
Bonetti A, Tirelli F, Catapano A, Dazzi D, Dei Cas A, Solito F, et al. Side effects of anabolic androgenic steroids abuse. Int J Sports Med. 2007; Epub ahead of print.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Nasr, J., Ahmad, J. Severe Cholestasis and Renal Failure Associated with the Use of the Designer Steroid Superdrol™ (Methasteron™): A Case Report and Literature Review. Dig Dis Sci 54, 1144–1146 (2009). https://doi.org/10.1007/s10620-008-0457-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10620-008-0457-x